| Name | Title | Contact Details |
|---|
Central Peninsula Hospital, Inc., an acute care hospital, provides patient and resident centered care services serving the Central Peninsula area. It offers emergency care, anesthesia, emergency medicine, family medicine, ENT, general surgery, internal medicine, neurology, OB/GYN, ophthalmology, orthopedics, pathology, pediatrics, podiatry, psychiatry, and radiology services; and behavioral health services that include depression screenings, substance abuse treatment, and substance abuse treatment services. The company also provides imaging services that include diagnostic imaging, digital mammography examinations, computer axial tomography procedures, ultrasound/sonography, nuclear medicine, and magnetic resonance imaging; physical, occupational, speech, and massage therapy services; outpatient weight loss, walking and exercise programs, cardiac rehabilitation, and diabetes management services; and diabetes education services. In addition, it offers family birth center services; laboratory services that include chemistry, hematology, transfusion medicine, serology, urinalysis, microbiology, and molecular biology testing; various treatments to outpatients include chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement; and sleep center services. Central Peninsula Hospital, Inc. was formerly known as Central Peninsula General Hospital, Inc. The company was founded in 1971 and is based in Soldotna, Alaska with practices in Kenai and Soldotna, Alaska.
Wish Recovery is a luxury rehab and detox facility in Los Angeles that offers personalized and comprehensive care for individuals struggling with alcohol and drug addiction.
Lawndale Christian Health Center is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.